CACLP Announces New Date and Venue for the Highly Anticipated 2025 Event
|
By LabMedica International staff writers Posted on 14 Oct 2024 |

Impressive numbers from CACLP 2024
In March 2024, the tradeshows were a resounding success, showcasing a diverse array of products and technologies from participants. The events drew an impressive 1,346 exhibitors and 42,751 visitors from China and 40 other countries, all gathered in a sprawling exhibition space of 130,000 sqm.
A series of academic activities featured 125 scientific lectures with 315 academic speakers and attracted over 5,000 delegates. These activities garnered 462,150 online views through CACLP’s WeChat channels and app.
Hangzhou: the ideal host for CACLP 2025
The upcoming event will return to Hangzhou, offering global participants a convenient and enriching experience in the newly opened Hangzhou Grand Convention & Exhibition Center.
Located in the heart of the economically vibrant Yangtze River Delta, Hangzhou offers convenient transportation, advanced innovation, and abundant natural and cultural resources. This enchanting city provides an ideal environment for the IVD industry. There are 6,626 medical and healthcare institutions in Hangzhou, including 414 hospitals and 27 top-tier (Grade A, Level 3) hospitals. Hangzhou has also pioneered China’s first dedicated IVD industry promotion institute to bolster local industry development.
With China’s favorable visa-free policy, international participants will find it easier than ever to join, and discover an optimal setting for collaboration, extensive networking, and exploration of the latest market trends and innovations.
Academic Highlights in Hangzhou
Numerous professionals across the whole IVD industry chain are expected take part in the concurrent academic activities, such as the 10th China Experimental Medicine Conference (CEMC) and series sessions and the 12th China IVD Industry Development Conference (CIIDC) and series forums.
These activities will include in-depth discussions on hot topics in laboratory medicine and IVD, with renowned experts and scholars presenting cutting-edge research findings, while industry leaders exchange valuable experiences.
"Bringing IVD people together!" embodies our commitment to always foster unity and progress within the industry. Join us in Hangzhou for CACLP 2025!
Interested in exhibiting or seeking more information? Leave your message here and we will get back to you very soon: https://en.caclp.com/exhibit-reserve.html
About GL events
GL events is a world-class leading provider of integrated solutions and services for events operating across the 3 major core divisions: Venues (venue management), Exhibitions (exhibition organizing) and Live (event services).
Through its wide global network made up of more than 90 offices, with organizing over 480 proprietary trade fair and events, managing more than 60 venues, and staging more than 4,200 events every year, GL events Group is a critical force for city promotion of 28 MICE destinations.
Present on five continents with operations in more than 20 countries, GL events has over 5,119 employees. Listed on the Eurolist Euronext Compartment B (Paris Stock Exchange), GL events had a turnover of €1.315bn in 2022.
About CACLP
Debut launched in 1991, China International In Vitro Diagnostic Expo by CACLP, is well established as one of the largest exhibitions in the in vitro diagnostic industry worldwide. China IVD Supply Chain Expo, successfully launched in 2021, further expands the product sectors from upstream to downstream. With a great number of high-level academic and educational programs held concurrently onsite, and year-round promotional solutions, CACLP proves itself as one of the most important platforms for global IVD players.
In 2020, CACLP formed the joint-venture company with GL events to start the internationalism strategy.
Latest Focus News
- Join TianLong at ADLM 2024 to Explore the Latest Diagnostic Innovations!
- Tianlong was Showcased in the METROLOGIA LAB SUMMIT and the SBBQ 53rd Annual Meeting in Brazil with Integrated PCR Lab Solutions
- Tianlong’s Latest All-in-one Molecular Diagnosis system - Panall 8000 Open System
- Meet TianLong at the 73rd Annual Convention of Philippine Society of Pathologist
- TianLong Participated in the International Medical Congress of SCO Countries in Kyrgyzstan
- TianLong HPV Nucleic Acid Detection Kit Could Enable Early Detection of Cervical Cancer
- Meet TianLong’s NEWLY LAUNCHED Real-Time PCR System - Gentier X3 Series
- TianLong Solution Facilitates the Prevention and Control of Livestock Diseases
- TianLong Solution Facilitates the Prevention and Control of Livestock Diseases
- Tianlong Showcases Latest Real-Time PCR System and Innovative Molecular Diagnostic Solutions at MEDICA 2023
- TianLong Will Exhibit at MEDICA 2023 in Messe Düsseldorf of Germany
- Tianlong at PhilMedical 2023 Expo | More to Expect!
- INVITATION! Meet us at the Brazilian Society of Clinical Analysis 2023
- Good News!- Tianlong has helped build up the HCV&HBV detection line for hospitals in northern Thailand!
- PANA9600X Automatic Nucleic Acid Workstation
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read morePathology
view channel
Engineered Yeast Cells Enable Rapid Testing of Cancer Immunotherapy
Developing new cancer immunotherapies is a slow, costly, and high-risk process, particularly for CAR T cell treatments that must precisely recognize cancer-specific antigens. Small differences in tumor... Read more
First-Of-Its-Kind Test Identifies Autism Risk at Birth
Autism spectrum disorder is treatable, and extensive research shows that early intervention can significantly improve cognitive, social, and behavioral outcomes. Yet in the United States, the average age... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







